Follicular Lymphoma
News
Cortactin expression aids in CLL-MCL differential
Cortactin, a cytoskeleton-remodeling adapter protein, is expressed on most CLL cells, but not similar-appearing MCL cells.
News
Biosimilar deemed equivalent to rituximab in FL
Phase 3 results suggest the biosimilar product CT-P10 is equivalent to rituximab in patients with low-tumor-burden follicular lymphoma (FL)....
News
Elderly NHL patients have higher NRM after HSCT
A retrospective study suggests elderly patients with non-Hodgkin lymphoma (NHL) are more likely to die, but not relapse, within a year of...
News
Rituximab biosimilar looks equivalent in follicular lymphoma
CT-P10 has been recommended for approval in the U.S. by the FDA’s Oncologic Drugs Advisory Committee.
News
R-CHOP effective as first-line treatment in FL
Long-term data suggest R-CHOP can be effective as first-line treatment for patients with follicular lymphoma (FL). In a phase 2-3 trial,...
News
R-CHOP looks viable as first line in follicular lymphoma
Long-term follow-up of a randomized trial showed durable efficacy of R-CHOP with no increase in histological transformation or secondary cancers...
News
Combo appears safe, active in rel/ref NHL
The combination of Hu5F9-G4 (5F9) and rituximab was considered safe and produced durable complete responses (CRs) in patients with relapsed or...
News
Sandoz won’t seek U.S. approval for rituximab biosimilar
Sandoz has decided not to pursue U.S. approval for its rituximab product (GP2013), a proposed biosimiliar of Rituxan/Mabthera. GP2013 (Rixathon,...
News
Sandoz halts pursuit of U.S. approval for rituximab biosimilar
News
Checkpoint inhibitor plus rituximab is active in non-Hodgkin lymphoma
Mainly low-grade toxic effects were seen on treatment with Hu5F9-G4 and rituximab in the study of relapsed and refractory patients.